NEW YORK (GenomeWeb) –GenePOC announced this week that Swiss pharmaceutical company Debiopharm has invested "tens of millions of dollars" into accelerating development of the Quebec City-based firm's molecular diagnostic platform and infectious disease assays.
The new funding will be used to support commercialization as well as to "continue our new assay development and have a constant flow of approximately two assays per year launched into the market," Herbert Torfs, GenePOC's vice president of business development and strategy, told GenomeWeb in an email.